Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in our first novel combination regimen that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Arbutus has a very broad HBV product pipeline against encompassing direct antiviral, host targeting and immune-based approaches, which include the following programs: capsid inhibitors, HBV RNA destabilizer and additional pre-clinical assets.
October 3 2019
September 26 2019